Vignesh Packiam, MD, discusses strategies to manage intravesical therapy toxicity in NMIBC, improve treatment tolerability, and preserve bladder function.
|Videos|September 28, 2021
Dr. Klotz weighs in on the future of prostate cancer testing
Author(s)Urology Times staff
Advertisement
In this video, Laurence Klotz, MD, FRCSC, discusses the miR Sentinel PCC4 Test and how it could change the future of prostate cancer testing. Klotz is a professor of surgery at the University of Toronto, and the chair of prostate cancer research at the Sunnybrook Health Sciences Centre, Ontario, Canada.
Advertisement
Related to this article
Sandip M. Prasad, MD, MPhil, discusses the safety profile of mitomycin intravesical solution, including common adverse events and patient counseling during chemoablation for NMIBC.
These FAQs outline key recommendations and practical takeaways from the AUA/SUFU/AUGS Genitourinary Syndrome of Menopause guideline.
Sandip M. Prasad, MD, MPhil, discusses 3-year ENVISION trial data showing durable responses with mitomycin intravesical solution for recurrent LG-IR-NMIBC.
Armine K. Smith, MD, discusses sexual health counseling, sex-specific considerations, and organ-preserving approaches for patients undergoing radical cystectomy.
This approval expands the label for nogapendekin alfa inbakicept to include patients with high-grade papillary-only tumors.
Melissa Hadley Barrett discusses real-world outcomes and tolerability of intranasal vardenafil for men with persistent erectile dysfunction despite prior standard therapy.
The completion of the first procedure marks the beginning of a controlled US commercial release.
Advertisement
Advertisement
Trending on Urology Times
1
Study assesses real-world outcomes with intranasal vardenafil for ED
2
Three-year data show durable responses with mitomycin intravesical solution
3
Urocross Expander System enters US commercial use for symptomatic BPH
4
Matching mCSPC treatment to the patient, not just the trial data
5